Youth FORWARD Phase 1 YRI and EPP Study

计划入组 297 人 · 首次发布于 2018 年 7 月 27 日

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

计划入组 286 人 · 首次发布于 2021 年 8 月 16 日

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

计划入组 184 人 · 首次发布于 2020 年 5 月 26 日

EPP-001

EPP (AureoGen Biosciences)

Afamelanotide(Scenesse)

C₇₈H₁₁₁N₂₁O₁₉

Clinuvel Pharmaceuticals Ltd

Australia

Universitätsklinikum Hamburg-Eppendorf

Germany

ELIM PEDIATRIC PHARMACEUTICALS INC.

United States

CLINUVEL Seeks Canadian Approval for SCENESSE® in Erythropoietic Protoporphyria

Disc Medicine Announces End-of-Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria

SCENESSE® (Afamelanotide) Approved by Health Canada for Erythropoietic Protoporphyria